# NCT06343402 (NCT06343402)

> Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06343402
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Conditions: Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; NSCLC; KRAS G12C; Metastatic Lung Cancer; Advanced Lung Carcinoma
- Interventions: BBO-8520; Pembrolizumab; BBO-10203
- Enrollment: 350
- Primary outcome: Adverse Events
- Primary outcome: Dose-limiting toxicities (DLTs)

## Commentary we found

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06343402